+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Renal cell cancer (RCC) disease forecast and market analysis to 2038

  • ID: 3797427
  • Report
  • Region: Global
  • 578 pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
Renal cell carcinoma (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney tumors are RCC, with other types including transitional cell carcinoma of the renal pelvis and Wilms tumor (nephroblastoma). The incidence of RCC is higher in those over the age of 60 years, suggesting that the aging population may play a significant role in current and future disease burden. Overall, RCC incidence rates have been steadily increasing in both men and women in the US, Japan, and five major EU markets since the 1970s.

Market Snapshot
  • The PD-1/PD-L1 class is set to experience significant growth, with annual sales forecast to reach $3.2bn by 2026.
  • Sutent continues to be the most widely prescribed therapy in locally advanced and metastatic RCC.
  • Incident cases of RCC are expected to increase by around a quarter during 2018–38.
  • Numerous therapies will soon experience generic erosion with the expiries of key patents.
  • PD-1/PD-L1 therapies are set to dominate the first-line treatment of advanced RC
  • Combination therapies pose challenges for payers.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
  • Recent Forecast Updates
  • Market Dynamics
  • Forecast And Future Trends
  • Market Definition And Methodology
  • Primary Research Methodology
  • Bibliography
  • Product Profile: Afinitor
  • Product Profile: Avastin
  • Product Profile (Late Stage): Bavencio
  • Product Profile (Late Stage): Cb-839
  • Product Profile: Cabometyx
  • Product Profile: Fotivda
  • Product Profile: Inlyta
  • Product Profile (Late Stage): Keytruda
  • Product Profile: Lenvima
  • Product Profile: Nexavar
  • Product Profile: Opdivo
  • Product Profile: Sutent
  • Product Profile (Late Stage): Tecentriq
  • Product Profile: Torisel
  • Product Profile: Votrient
  • Product Profile (Late Stage): Abexinostat
TREATMENT: RENAL CELL CARCINOMA (Published on 16 February 2018)
  • Overview
  • Executive Summary
  • Primary Research Methodology
  • Disease Definition And Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends
EPIDEMIOLOGY: RENAL CELL CARCINOMA (Published on 06 March 2019)
  • Overview
  • Disease Background
  • Methodology
  • Forecast
  • Bibliography
  • Appendix: Additional Sources
MARKETED DRUGS: RENAL CELL CARCINOMA (Published on 06 March 2019)
  • Overview
  • Product Overview
  • Product Profile: Afinitor
  • Product Profile: Avastin
  • Product Profile: Cabometyx
  • Product Profile: Fotivda
  • Product Profile: Inlyta
  • Product Profile: Lenvima
  • Product Profile: Nexavar
  • Product Profile: Opdivo
  • Product Profile: Sutent
  • Product Profile: Torisel
  • Product Profile: Votrient
RENAL CELL CANCER PRICING, REIMBURSEMENT, AND ACCESS (Published on 22 August 2018)
  • Overview
  • Regulatory Labels
  • Global Access Levers
  • Evidence And Value
  • Access To Recently Approved And Pipeline Drugs
  • Pricing
  • Us
  • Canada
  • Japan
  • France
  • Germany
  • Italy
  • Spain
  • Uk
  • Methodology
PIPELINE: RENAL CELL CARCINOMA (Published on 06 March 2019)
  • Overview
  • Clinical Pipeline Overview
  • Additional Pharma Intelligence Pipeline Resources
  • Product Profile (Late Stage): Bavencio
  • Product Profile (Late Stage): Cb-839
  • Product Profile (Late Stage): Keytruda
  • Product Profile (Late Stage): Tecentriq
  • Product Profile (Late Stage): Abexinostat
LIST OF FIGURES
Figure 1: RCC – current and future market dynamics analysis
Figure 2: The author's assessment summary of key marketed and pipeline drugs for RCC
Figure 3: RCC sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Sales of Bavencio, Keytruda, Opdivo, and Tecentriq in RCC across the US, Japan, and five major EU markets, 2017–26
Figure 5: Sales of Sutent in RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 6: Sales of branded drugs expected to face biosimilar or generic competition during the forecast period, 2017–26
Figure 7: Sales of therapies expected to be available in combination with PD-1/PD-L1 therapies, by drug, 2017–26
Figure 8: Patient-based forecast methodology for RCC
Figure 9: Price sources and calculations, by country
Figure 10: Afinitor for RCC – SWOT analysis
Figure 11: The author's drug assessment summary of Afinitor for RCC
Figure 12: The author's drug assessment summary of Afinitor for RCC
Figure 13: Afinitor sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 14: Avastin for RCC – SWOT analysis
Figure 15: The author's drug assessment summary of Avastin for RCC
Figure 16: The author's drug assessment summary of Avastin for RCC
Figure 17: Avastin sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 18: Bavencio for RCC – SWOT analysis
Figure 19: The author's drug assessment summary of Bavencio for RCC
Figure 20: The author's drug assessment summary of Bavencio for RCC
Figure 21: Bavencio sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 22: CB-839 for RCC – SWOT analysis
Figure 23: The author's drug assessment summary of CB-839 for RCC
Figure 24: The author's drug assessment summary of CB-839 for RCC
Figure 25: CB-839 sales for RCC in the US, 2017–26
Figure 26: Cabometyx for RCC – SWOT analysis
Figure 27: The author's drug assessment summary of Cabometyx for RCC
Figure 28: The author's drug assessment summary of Cabometyx for RCC
Figure 29: Cabometyx sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 30: Fotivda for RCC – SWOT analysis
Figure 31: The author's drug assessment summary of Fotivda for RCC
Figure 32: The author's drug assessment summary of Fotivda for RCC
Figure 33: Fotivda sales for RCC across the five major EU markets, by country, 2017–26
Figure 34: Inlyta for RCC – SWOT analysis
Figure 35: The author's drug assessment summary of Inlyta for RCC
Figure 36: The author's drug assessment summary of Inlyta for RCC
Figure 37: Inlyta sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 38: Keytruda for RCC – SWOT analysis
Figure 39: The author's drug assessment summary of Keytruda for RCC
Figure 40: The author's drug assessment summary of Keytruda for RCC
Figure 41: Keytruda sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 42: Lenvima for RCC – SWOT analysis
Figure 43: The author's drug assessment summary of Lenvima for RCC
Figure 44: The author's drug assessment summary of Lenvima for RCC
Figure 45: Lenvima sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 46: Nexavar for RCC – SWOT analysis
Figure 47: The author's drug assessment summary of Nexavar for RCC
Figure 48: The author's drug assessment summary of Nexavar for RCC
Figure 49: Nexavar sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 50: Opdivo for RCC – SWOT analysis
Figure 51: The author's drug assessment summary of Opdivo for RCC
Figure 52: The author's drug assessment summary of Opdivo for RCC
Figure 53: Opdivo sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 54: Sutent for RCC – SWOT analysis
Figure 55: The author's drug assessment summary of Sutent for RCC
Figure 56: The author's drug assessment summary of Sutent for RCC
Figure 57: Sutent sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 58: Tecentriq for RCC – SWOT analysis
Figure 59: The author's drug assessment summary of Tecentriq for RCC
Figure 60: The author's drug assessment summary of Tecentriq for RCC
Figure 61: Tecentriq sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 62: Torisel for RCC – SWOT analysis
Figure 63: The author's drug assessment summary of Torisel for RCC
Figure 64: The author's drug assessment summary of Torisel for RCC
Figure 65: Torisel sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 66: Votrient for RCC – SWOT analysis
Figure 67: The author's drug assessment summary of Votrient for RCC
Figure 68: The author's drug assessment summary of Votrient for RCC
Figure 69: Votrient sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 70: Abexinostat for RCC – SWOT analysis
Figure 71: The author's drug assessment summary of abexinostat for RCC
Figure 72: The author's drug assessment summary of abexinostat for RCC
Figure 73: Abexinostat sales for RCC in the US, 2017–26
Figure 74: Distribution of RCC patients across the US, Japan, and five major EU markets, by stage and country
Figure 75: Percentage of Stage I–III RCC patients receiving each type of treatment, by country
Figure 76: Percentage of Stage IV RCC patients receiving each treatment type at first-line, by country
Figure 77: Top three regimens used in the first-line treatment of Stage IV RCC patients, by country
Figure 78: Percentage of Stage IV RCC patients currently receiving each line of therapy, by country
Figure 79: Top three regimens used in the second-line treatment of Stage IV RCC, by country
Figure 80: Top three regimens used in the third-line treatment of Stage IV RCC, by country
Figure 81: Percentage of local-relapse RCC patients receiving each treatment type at first-line, by country
Figure 82: Percentage of local-relapse RCC patients receiving neoadjuvant therapy, adjuvant therapy, or both, by country
Figure 83: Top three regimens used in the first-line treatment of local-relapse RCC patients, by country
Figure 84: Percentage of distant-relapse RCC patients receiving each treatment type at first-line, by country
Figure 85: Top three regimens used in the first-line treatment of distant-relapse RCC patients, by country
Figure 86: Percentage of distant-relapse RCC patients currently receiving each line of therapy, by country
Figure 87: Top three regimens used in the second-line treatment of distant-relapse RCC patients, by country
Figure 88: Top three regimens used in the third-line treatment of distant-relapse RCC patients, by country
Figure 89: Trends in incident cases of RCC in the US, Japan, and five major EU markets, by country, 2018–38
Figure 90: Afinitor for RCC – SWOT analysis
Figure 91: The author's drug assessment summary of Afinitor for RCC
Figure 92: The author's drug assessment summary of Afinitor for RCC
Figure 93: Afinitor sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 94: Avastin for RCC – SWOT analysis
Figure 95: The author's drug assessment summary of Avastin for RCC
Figure 96: The author's drug assessment summary of Avastin for RCC
Figure 97: Avastin sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 98: Cabometyx for RCC – SWOT analysis
Figure 99: The author's drug assessment summary of Cabometyx for RCC
Figure 100: The author's drug assessment summary of Cabometyx for RCC
Figure 101: Cabometyx sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 102: Fotivda for RCC – SWOT analysis
Figure 103: The author's drug assessment summary of Fotivda for RCC
Figure 104: The author's drug assessment summary of Fotivda for RCC
Figure 105: Fotivda sales for RCC across the five major EU markets, by country, 2017–26
Figure 106: Inlyta for RCC – SWOT analysis
Figure 107: The author's drug assessment summary of Inlyta for RCC
Figure 108: The author's drug assessment summary of Inlyta for RCC
Figure 109: Inlyta sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 110: Lenvima for RCC – SWOT analysis
Figure 111: The author's drug assessment summary of Lenvima for RCC
Figure 112: The author's drug assessment summary of Lenvima for RCC
Figure 113: Lenvima sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 114: Nexavar for RCC – SWOT analysis
Figure 115: The author's drug assessment summary of Nexavar for RCC
Figure 116: The author's drug assessment summary of Nexavar for RCC
Figure 117: Nexavar sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 118: Opdivo for RCC – SWOT analysis
Figure 119: The author's drug assessment summary of Opdivo for RCC
Figure 120: The author's drug assessment summary of Opdivo for RCC
Figure 121: Opdivo sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 122: Sutent for RCC – SWOT analysis
Figure 123: The author's drug assessment summary of Sutent for RCC
Figure 124: The author's drug assessment summary of Sutent for RCC
Figure 125: Sutent sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 126: Torisel for RCC – SWOT analysis
Figure 127: The author's drug assessment summary of Torisel for RCC
Figure 128: The author's drug assessment summary of Torisel for RCC
Figure 129: Torisel sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 130: Votrient for RCC – SWOT analysis
Figure 131: The author's drug assessment summary of Votrient for RCC
Figure 132: The author's drug assessment summary of Votrient for RCC
Figure 133: Votrient sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 134: Price sources and calculations for the US and five major EU markets, by country
Figure 135: Bavencio for RCC – SWOT analysis
Figure 136: The author's drug assessment summary of Bavencio for RCC
Figure 137: The author's drug assessment summary of Bavencio for RCC
Figure 138: Bavencio sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 139: CB-839 for RCC – SWOT analysis
Figure 140: The author's drug assessment summary of CB-839 for RCC
Figure 141: The author's drug assessment summary of CB-839 for RCC
Figure 142: CB-839 sales for RCC in the US, 2017–26
Figure 143: Keytruda for RCC – SWOT analysis
Figure 144: The author's drug assessment summary of Keytruda for RCC
Figure 145: The author's drug assessment summary of Keytruda for RCC
Figure 146: Keytruda sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 147: Tecentriq for RCC – SWOT analysis
Figure 148: The author's drug assessment summary of Tecentriq for RCC
Figure 149: The author's drug assessment summary of Tecentriq for RCC
Figure 150: Tecentriq sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 151: Abexinostat for RCC – SWOT analysis
Figure 152: The author's drug assessment summary of abexinostat for RCC
Figure 153: The author's drug assessment summary of abexinostat for RCC
Figure 154: Abexinostat sales for RCC in the US, 2017–26

LIST OF TABLES
Table 1: Exchange rates used for calculating prices
Table 2: Oncologists and urologists surveyed for the RCC primary research study, 2017
Table 3: Afinitor drug profile
Table 4: Afinitor Phase III data in RCC
Table 5: Afinitor ongoing trials in RCC
Table 6: Afinitor sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 7: Avastin drug profile
Table 8: Avastin Phase III data in RCC
Table 9: Avastin sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 10: Bavencio drug profile
Table 11: Bavencio Phase III data in RCC
Table 12: Bavencio sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 13: CB-839 drug profile
Table 14: CB-839 Phase II trials in RCC
Table 15: CB-839 sales for RCC in the US ($m), 2017–26
Table 16: Cabometyx drug profile
Table 17: Cabometyx Phase III data in RCC
Table 18: Cabometyx’s ongoing trials in RCC
Table 19: Cabometyx sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 20: Fotivda drug profile
Table 21: Fotivda Phase III data in RCC
Table 22: Fotivda sales for RCC across the five major EU markets, by country ($m), 2017–26
Table 23: Inlyta drug profile
Table 24: Inlyta Phase III data in RCC
Table 25: Inlyta Phase III data in RCC
Table 26: Inlyta Phase III data in RCC
Table 27: Inlyta sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 28: Keytruda drug profile
Table 29: Keytruda Phase III data in RCC
Table 30: Keytruda Phase III trials in RCC
Table 31: Keytruda sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 32: Lenvima drug profile
Table 33: Lenvima pivotal trial data in RCC
Table 34: Lenvima ongoing trials in RCC
Table 35: Lenvima sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 36: Nexavar drug profile
Table 37: Nexavar pivotal trial data in RCC
Table 38: Nexavar Phase III data in RCC
Table 39: Nexavar sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 40: Opdivo drug profile
Table 41: Opdivo Phase III data in RCC
Table 42: Opdivo ongoing trials in RCC
Table 43: Opdivo sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 44: Sutent drug profile
Table 45: Sutent pivotal trial data in RCC
Table 46: Sutent Phase III data in RCC
Table 47: Sutent sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 48: Tecentriq drug profile
Table 49: Tecentriq Phase III data in RCC
Table 50: Tecentriq Phase III trials in RCC
Table 51: Tecentriq sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 52: Torisel drug profile
Table 53: Torisel pivotal trial data in RCC
Table 54: Torisel Phase III data in RCC
Table 55: Torisel sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 56: Votrient drug profile
Table 57: Votrient pivotal trial data in RCC
Table 58: Votrient Phase III data in RCC
Table 59: Votrient ongoing trials in RCC
Table 60: Votrient sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 61: Abexinostat drug profile
Table 62: Abexinostat Phase III data in RCC
Table 63: Abexinostat sales for RCC in the US ($m), 2017–26
Table 64: Oncologists and urologists surveyed for the RCC primary research study, 2017
Table 65: RCC five-year survival rates, by stage at diagnosis
Table 66: TNM classification, by stage at diagnosis
Table 67: Leading treatments for RCC across the US, Japan, and five major EU markets
Table 68: Cancer registry databases used as a source of RCC incidence data, by country
Table 69: Forecasting methodology for RCC incidence, by country, age group, and gender
Table 70: Sources of survival data used to estimate RCC prevalence, by country
Table 71: Validation of forecasted RCC incidence estimates against benchmark case numbers
Table 72: Incident cases of RCC in the US, Japan, and five major EU markets, by country, 2018–38
Table 73: Profiled key marketed drugs for RCC
Table 74: Afinitor drug profile
Table 75: Afinitor Phase III data in RCC
Table 76: Afinitor ongoing trials in RCC
Table 77: Afinitor sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 78: Avastin drug profile
Table 79: Avastin Phase III data in RCC
Table 80: Avastin sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 81: Cabometyx drug profile
Table 82: Cabometyx Phase III data in RCC
Table 83: Cabometyx’s ongoing trials in RCC
Table 84: Cabometyx sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 85: Fotivda drug profile
Table 86: Fotivda Phase III data in RCC
Table 87: Fotivda sales for RCC across the five major EU markets, by country ($m), 2017–26
Table 88: Inlyta drug profile
Table 89: Inlyta Phase III data in RCC
Table 90: Inlyta Phase III data in RCC
Table 91: Inlyta Phase III data in RCC
Table 92: Inlyta sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 93: Lenvima drug profile
Table 94: Lenvima pivotal trial data in RCC
Table 95: Lenvima ongoing trials in RCC
Table 96: Lenvima sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 97: Nexavar drug profile
Table 98: Nexavar pivotal trial data in RCC
Table 99: Nexavar Phase III data in RCC
Table 100: Nexavar sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 101: Opdivo drug profile
Table 102: Opdivo Phase III data in RCC
Table 103: Opdivo ongoing trials in RCC
Table 104: Opdivo sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 105: Sutent drug profile
Table 106: Sutent pivotal trial data in RCC
Table 107: Sutent Phase III data in RCC
Table 108: Sutent sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 109: Torisel drug profile
Table 110: Torisel pivotal trial data in RCC
Table 111: Torisel Phase III data in RCC
Table 112: Torisel sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 113: Votrient drug profile
Table 114: Votrient pivotal trial data in RCC
Table 115: Votrient Phase III data in RCC
Table 116: Votrient ongoing trials in RCC
Table 117: Votrient sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 118: Marketed products and their approved indications for RCC in the US, Japan, and five major EU markets
Table 119: Levers impacting access to RCC drugs in the US and five major EU markets, by country
Table 120: Pricing, market access, and reimbursement strategies for combination therapies
Table 121: Importance of key endpoints in RCC clinical trial design, by country
Table 122: Likely reimbursement of first-line combination therapies in RCC, by country
Table 123: Pricing and reimbursement prospects for Cabometyx in the first line, by country
Table 124: Preference for second-line treatment: Opdivo versus Cabometyx, by country
Table 125: Pricing strategies for the PD-1 inhibitors, by country
Table 126: Pricing of key RCC drugs in the US, Japan, and five major EU markets, by country
Table 127: NCCN guidelines for RCC medicines
Table 128: Japan - pricing premiums given to medicines that can demonstrate benefit over comparators
Table 129: Price calculation methodologies for RCC drugs in Japan launched after 2008
Table 130: Transparency Committee’s ASMR ratings and pricing implications
Table 131: Transparency Committee's SMR ratings and pricing implications
Table 132: AIFA web registry and managed entry agreements for RCC drugs
Table 133: Spanish Society of Hospital Pharmacy ratings
Table 134: Exchange rates used for calculating drug prices
Table 135: Profiled pipeline products in development for RCC
Table 136: Bavencio drug profile
Table 137: Bavencio Phase III data in RCC
Table 138: Bavencio sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 139: CB-839 drug profile
Table 140: CB-839 Phase II trials in RCC
Table 141: CB-839 sales for RCC in the US ($m), 2017–26
Table 142: Keytruda drug profile
Table 143: Keytruda Phase III data in RCC
Table 144: Keytruda Phase III trials in RCC
Table 145: Keytruda sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 146: Tecentriq drug profile
Table 147: Tecentriq Phase III data in RCC
Table 148: Tecentriq Phase III trials in RCC
Table 149: Tecentriq sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 150: Abexinostat drug profile
Table 151: Abexinostat Phase III data in RCC
Table 152: Abexinostat sales for RCC in the US ($m), 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll